Gene-directed enzyme prodrug therapy: A current assessment

SR McKeown, C Ward, T Robson

    Research output: Contribution to journalArticle

    21 Citations (Scopus)

    Abstract

    Gene-directed enzyme prodrug therapy involves tumor-specific delivery of a gene encoding a drug-metabolizing enzyme allowing metabolism of a non-toxic prodrug to a toxic species directly within tumor cells. This review covers the wide range of enzyme-prodrug combinations currently under preclinical and clinical investigation. Issues of tumor specificity and enhanced cytotoxicity through bystander effects will be discussed.
    LanguageEnglish
    Pages421-435
    JournalCurrent Opinion in Molecular Therapeutics
    Volume6
    Issue number4
    Publication statusPublished - Aug 2004

    Fingerprint

    Enzyme Therapy
    Prodrugs
    Bystander Effect
    Genes
    Neoplasms
    Poisons
    Enzymes
    Pharmaceutical Preparations

    Cite this

    McKeown, SR ; Ward, C ; Robson, T. / Gene-directed enzyme prodrug therapy: A current assessment. In: Current Opinion in Molecular Therapeutics. 2004 ; Vol. 6, No. 4. pp. 421-435.
    @article{d0c09d933ec147f1a4a0a1aba8df1c9f,
    title = "Gene-directed enzyme prodrug therapy: A current assessment",
    abstract = "Gene-directed enzyme prodrug therapy involves tumor-specific delivery of a gene encoding a drug-metabolizing enzyme allowing metabolism of a non-toxic prodrug to a toxic species directly within tumor cells. This review covers the wide range of enzyme-prodrug combinations currently under preclinical and clinical investigation. Issues of tumor specificity and enhanced cytotoxicity through bystander effects will be discussed.",
    author = "SR McKeown and C Ward and T Robson",
    year = "2004",
    month = "8",
    language = "English",
    volume = "6",
    pages = "421--435",
    journal = "Current Opinion in Molecular Therapeutics",
    issn = "1464-8431",
    number = "4",

    }

    McKeown, SR, Ward, C & Robson, T 2004, 'Gene-directed enzyme prodrug therapy: A current assessment', Current Opinion in Molecular Therapeutics, vol. 6, no. 4, pp. 421-435.

    Gene-directed enzyme prodrug therapy: A current assessment. / McKeown, SR; Ward, C; Robson, T.

    In: Current Opinion in Molecular Therapeutics, Vol. 6, No. 4, 08.2004, p. 421-435.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Gene-directed enzyme prodrug therapy: A current assessment

    AU - McKeown, SR

    AU - Ward, C

    AU - Robson, T

    PY - 2004/8

    Y1 - 2004/8

    N2 - Gene-directed enzyme prodrug therapy involves tumor-specific delivery of a gene encoding a drug-metabolizing enzyme allowing metabolism of a non-toxic prodrug to a toxic species directly within tumor cells. This review covers the wide range of enzyme-prodrug combinations currently under preclinical and clinical investigation. Issues of tumor specificity and enhanced cytotoxicity through bystander effects will be discussed.

    AB - Gene-directed enzyme prodrug therapy involves tumor-specific delivery of a gene encoding a drug-metabolizing enzyme allowing metabolism of a non-toxic prodrug to a toxic species directly within tumor cells. This review covers the wide range of enzyme-prodrug combinations currently under preclinical and clinical investigation. Issues of tumor specificity and enhanced cytotoxicity through bystander effects will be discussed.

    M3 - Article

    VL - 6

    SP - 421

    EP - 435

    JO - Current Opinion in Molecular Therapeutics

    T2 - Current Opinion in Molecular Therapeutics

    JF - Current Opinion in Molecular Therapeutics

    SN - 1464-8431

    IS - 4

    ER -